Certain SLCO1B1 variants associated with enhanced clearance of methotrexate increase the risk of gastrointestinal toxicity when this compound is used to treat children with acute lymphoblastic leukemia [30]. The gene discussed is SLCO1B1; the disease is acute lymphoblastic leukemia.